Search Results for "insulin"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for insulin. Results 131 to 140 of 151 total matches.
Rosiglitazone (Avandia) Revisited
The Medical Letter on Drugs and Therapeutics • Mar 08, 2010 (Issue 1333)
, 2010).
THIAZOLIDINEDIONES — The thiazolidinediones
rosiglitazone and pioglitazone (Actos) are insulin ...
The cardiovascular safety of the thiazolidinedione rosiglitazone (Avandia – GlaxoSmithKline) is in the news again, with some authorities calling for its removal from the market (New York Times, February 19, 2010).
Resveratrol
The Medical Letter on Drugs and Therapeutics • Sep 21, 2009 (Issue 1321)
insulin sensitivity, and increased survival.
4
A
study in non-obese laboratory mice found no increase ...
Resveratrol is a phytochemical found in the skin of red grapes and in many other plants, including berries, plums and peanuts. As a constituent of red wine, it has been associated with cardioprotective effects. Dietary supplements containing resveratrol are now being widely promoted as antioxidants that can prevent agerelated diseases.
Semaglutide (Ozempic) for Weight Loss
The Medical Letter on Drugs and Therapeutics • Apr 05, 2021 (Issue 1621)
glucose-dependent secretion of insulin,
suppress glucagon secretion, slow gastric emptying,
and promote ...
In recently published clinical trials, once-weekly
subcutaneous injection of the glucagon-like peptide 1
(GLP-1) receptor agonist semaglutide (Ozempic – Novo Nordisk), which is FDA-approved for treatment of
type 2 diabetes and to reduce the risk of major adverse
cardiovascular events in adults with type 2 diabetes
and established cardiovascular disease, has reduced
body weight significantly in patients with and without
type 2 diabetes when given in addition to lifestyle
intervention. Liraglutide (Saxenda), another GLP-1
receptor agonist, has been FDA-approved for chronic
weight...
Semaglutide (Wegovy) for MASH
The Medical Letter on Drugs and Therapeutics • Oct 13, 2025 (Issue 1739)
hepatic steatosis
and insulin sensitivity indirectly by reducing food
intake and body weight. They also ...
The injectable glucagon-like peptide-1 (GLP-1)
receptor agonist semaglutide (Wegovy) has received
accelerated approval from the FDA for treatment
of noncirrhotic metabolic dysfunction-associated
steatohepatitis (MASH; previously known as
nonalcoholic steatohepatitis [NASH]) with moderate to
advanced liver fibrosis in adults. It is the second drug
and the first GLP-1 receptor agonist to be approved in
the US for treatment of MASH; resmetirom (Rezdiffra),
a thyroid hormone receptor-beta agonist, was granted
accelerated approval for the same indication in 2024.
Med Lett Drugs Ther. 2025 Oct 13;67(1739):161-2 doi:10.58347/tml.2025.1739a | Show Introduction Hide Introduction
Drugs for Ovulation Induction
The Medical Letter on Drugs and Therapeutics • Oct 31, 2011 (Issue 1376)
syndrome (PCOS),
which is associated with obesity, hyperandrogenism,
and insulin resistance. Metformin ...
Infertility occurs in about 15% of couples. About one-third
of cases are due to problems with ovulation or other
female factors, another third are due to a male infertility
factor, and the remaining third are unexplained. In older
women, unexplained infertility is probably caused by
diminished quality and quantity of oocytes. The first
approach to treatment of female-factor infertility generally
is the use of drugs that stimulate oocyte production.
Sodium Zirconium Cyclosilicate (Lokelma) for Hyperkalemia
The Medical Letter on Drugs and Therapeutics • Dec 03, 2018 (Issue 1561)
, such as calcium, beta-agonists, and/or
insulin with glucose.5
CLINICAL STUDIES — FDA approval of SZC was
based ...
The FDA has approved sodium zirconium cyclosilicate
(Lokelma – AstraZeneca), an oral potassium binder that
exchanges hydrogen and sodium for potassium in the
gastrointestinal (GI) lumen, for treatment of non-life-threatening
hyperkalemia in adults. Sodium zirconium
cyclosilicate (SZC) is the third drug to be approved
for this indication; sodium polystyrene sulfonate and
patiromer (Veltassa) were approved earlier.
Contrave - A Combination of Bupropion and Naltrexone for Weight Loss
The Medical Letter on Drugs and Therapeutics • Nov 10, 2014 (Issue 1455)
circumference,
LDL-C, HDL-C, triglycerides, and insulin resistance
also improved significantly ...
The FDA has approved a fixed-dose combination of
the opioid receptor antagonist naltrexone (ReVia, and
others) and the antidepressant and smoking cessation
agent bupropion (Wellbutrin SR, Zyban, and others),
as Contrave (Orexigen/Takeda) for weight loss. The
combination was approved for use as an adjunct to
diet and increased physical activity in patients with a
body mass index (BMI) ≥30 kg/m2 or a BMI ≥27 kg/m2
and one or more weight-related comorbidities such as
hypertension, diabetes, or dyslipidemia. Naltrexone/bupropion is not a controlled...
Atazanavir (Reyataz) and Emtricitabine (Emtriva) for HIV Infection
The Medical Letter on Drugs and Therapeutics • Nov 10, 2003 (Issue 1169)
-term use will be less likely to cause the lipodystrophy and insulin resistance seen with other PIs ...
Atazanavir (Reyataz - Bristol-Myers Squibb), a new protease inhibitor (PI), and emtricitabine (Emtriva - Gilead), a nucleoside analogue reverse transcriptase inhibitor (NRTI) chemically similar to lamivudine, have been approved by the FDA for treatment of HIV-1 infection. Both are taken once daily, unlike most anti-HIV drugs.
Pharmaceutical Drug Overdose
Treatment Guidelines from The Medical Letter • Sep 01, 2006 (Issue 49)
. The adverse
effects of glucagon include vomiting, hyperglycemia
and hypokalemia.
14
High-dose insulin ...
Every pharmaceutical drug is a dose-dependent poison. This article describes the clinical presentation and treatment of some dangerous overdoses commonly reported in adults.
Coenzyme Q10
The Medical Letter on Drugs and Therapeutics • Feb 27, 2006 (Issue 1229)
(coenzyme Q10)
treatment on glycaemic control, insulin requirement and wellbeing in patients with Type 1 ...
Coenzyme Q10, a fat-soluble antioxidant also known as ubidecarenone, ubiquinone and CoQ10, is marketed as a dietary supplement in the US, both as a single ingredient and in various combination products.
